Neural patterns predicted which participants classified as high or low performers based on attention networks during the game. LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive ...

LOS ANGELES--(BUSINESS WIRE)-- Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular ...

Please provide your email address to receive an email when new articles are posted on . Neurotechnology firm Kernel and biopharmaceutical company Cybin announced promising pilot results from a ...

At last year's SPIE Photonics West, California-based neurotech start-up Kernel revealed the system architecture of its proposed Kernel Flux optically-pumped magnetometer platform designed to record ...

- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - LOS ANGELES & TORONTO--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) ...

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed ...

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S.

New feasibility study indicates that VR has the potential to drive physiological changes in the body and brain associated with pain relief LOS ANGELES, Feb. 8, 2024 /PRNewswire/ -- AppliedVR ®, a ...

Peering into the human brain has never been easy. For decades, neuroscientists have relied on heavy, expensive machines to measure blood flow and oxygen levels that reveal how the brain works. These ...

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that the first study visit has ...